AlphaMind Brands Inc is entering the functional mushrooms market.
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.